Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 64pembrolizumab 48Fluorouracil 44Capecitabine 38Nivolumab 33Leucovorin 32Paclitaxel 28Trastuzumab 19Docetaxel 18Cisplatin 18S 1 (combination) 16Bevacizumab 15Ramucirumab 13Irinotecan 13Drug Therapy 13tislelizumab 12Cyclophosphamide 12fludarabine 10Carboplatin 10Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 8sintilimab 8Specimen Handling 8Biopsy 8atezolizumab 7Surgical Procedures, Operative 7Gemcitabine 7zolbetuximab 6durvalumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × CA-4948 × 1 year × Clear all
NCT05187182 2026-04-27

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Washington University School of Medicine

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡